Center for the Study of Liver Cancer and Department of Hepatic Surgery, Anhui Provincial Hospital, Anhui Medical University, No 17 Lujiang Road, Hefei, 230001 Anhui, China.
Med Oncol. 2011 Dec;28 Suppl 1:S318-25. doi: 10.1007/s12032-010-9763-1. Epub 2010 Dec 3.
Extracellular matrix protein 1 (ECM1) is a glycoprotein involved in a number of biologic processes. To investigate the expression of ECM1 in hepatocellular carcinoma (HCC) and determine its correlation with tumor progression and prognosis, the expression levels of ECM1 in three HCC and one normal liver cell lines, tumor, and corresponding adjacent tissues from 18 HCC patients were analyzed by reverse transcription polymerase chain reaction (RT-PCR) and Western blotting. Immunohistochemistry assay was used to determine the expression of ECM1 in HCC and corresponding paracarcinomatous tissues from 77 patients. The results of Western blotting were consistent with the results from RT-PCR analysis of ECM1 mRNA expression. Among the four cell lines, the expression level in HCCLM3, which with the highest metastatic potential, was significantly higher than that with lower (P < 0.05); while ECM1 expression was not detected in normal liver cell line. Expression level of ECM1 was significantly increased in HCC compared with adjacent and normal liver tissues (P < 0.05). Immunohistochemically, the expression of ECM1 in HCC was judged to be positive in 57 (74.0%) cases, significantly higher than that in corresponding paracarcinomatous tissues (P < 0.01), and it was associated with tumor size (P = 0.036), number of tumor nodules (P = 0.048), TNM stage (P = 0.029), and vascular invasion (P = 0.007). In particular, the expression of ECM1 was found to be an independent factor for predicting overall and disease-free survival of HCC. The expression level of ECM1 was associated with metastatic potential of HCC, and its abnormal expression may be used as a predictive factor of unfavorable prognosis and recurrence for HCC after surgery.
细胞外基质蛋白 1(ECM1)是一种参与多种生物学过程的糖蛋白。为了研究 ECM1 在肝细胞癌(HCC)中的表达情况,并确定其与肿瘤进展和预后的关系,本研究采用逆转录聚合酶链反应(RT-PCR)和 Western blot 法检测了 3 株 HCC 细胞系和 1 株正常肝细胞系、肿瘤及 18 例 HCC 患者相应癌旁组织中 ECM1 的表达水平,并用免疫组化法检测了 77 例 HCC 及癌旁组织中 ECM1 的表达。Western blot 结果与 ECM1mRNA 表达的 RT-PCR 分析结果一致。在 4 株细胞系中,转移潜能最高的 HCCLM3 细胞系中 ECM1 的表达水平明显高于其他细胞系(P<0.05),而正常肝细胞系中未检测到 ECM1 的表达。与癌旁和正常肝组织相比,HCC 中 ECM1 的表达水平显著升高(P<0.05)。免疫组化结果显示,57 例(74.0%)HCC 组织中 ECM1 的表达为阳性,显著高于相应癌旁组织(P<0.01),与肿瘤大小(P=0.036)、肿瘤结节数目(P=0.048)、TNM 分期(P=0.029)和血管侵犯(P=0.007)有关。尤其值得注意的是,ECM1 的表达是预测 HCC 患者总生存和无病生存的独立因素。ECM1 的表达水平与 HCC 的转移潜能有关,其异常表达可能成为预测 HCC 患者术后不良预后和复发的指标。